L1 Capital Pty Ltd sold $69K of AVR (indirect holdings)

Anteris Technologies reported 30-day results from the EMBARK Study for its DurAVR heart valve, showing low pressure gradients, large valve openings, and no valve-related deaths. The study involved 22 patients with severe aortic stenosis. The company is also conducting the PARADIGM trial, a global study comparing DurAVR to existing valves.

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day results for its DurAVR THV in 22 patients, showing favorable hemodynamics, no moderate/severe leaks, and no valve-related deaths. The trial is ongoing, with the PARADIGM study comparing DurAVR to other TAVRs. According to the company, the results are promising for long-term outcomes.

Anteris Technologies (AVR) received German regulatory clearance to start the PARADIGM trial for its DurAVR heart valve. The trial will compare DurAVR to existing TAVRs in treating aortic stenosis. Germany's market size and expertise support patient recruitment. AVR stock closed at $6.18, up 2.15%, and is up 3.40% in overnight trading.

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.